Twist Bioscience Corporation TWST has priced its upsized underwritten public offering of 4.5 million at $55.00 per share, with gross proceeds of approximately $250 million.
- Earlier, the Company had announced the public offering of $200 million.
- The Offer price represents a discount of almost 11% from the last close price of $61.64 on Thursday.
- Underwriters have an option to purchase up to an additional 681,818 shares.
- Twist will use the proceeds, along with its existing cash, cash equivalents, and short-term investments, to scale its investment in its R&D organization.
- Also See: Twist Bioscience, Eleven Therapeutics Create Synthetic Viral RNA Molecules To Develop Antiviral Vaccines, Therapeutics.
- The Company also uses a portion of the net proceeds to acquire or invest in complementary businesses or products in-license.
- The offering will close by February 15.
- Price Action: TWST shares are down 3.10% at $59.73 during the market session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in